The Alpha-2 adrenergic receptor agonist with Delirium
Abstract
Delirium is a common clinical syndrome was found in in-patients which cause by acute brain dysfunction characterized by cognitive disorder and other behavioral problems. This problem can prolong the length of hospital stays or increase the cost of care. Antipsychotics are the first-line recommendation for delirium treatment, but the usage has been limited because of side effects such as extrapyramidal side effects, drug abuse, and respiratory depression. In another choice, alpha-2 adrenergic receptor agonists have been used as alternative agents for delirium treatment because they have sedative and analgesic effects and may decrease some side effects, especially respiratory suppression and drug abuse. Moreover, they are also able to reduce blood pressure too. However, the patients receiving their agent should be closely followed for hypotension and bradycardia.
References
Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009;5(4):210-20.
Hayhurst CJ, Pandharipande PP, Hughes CG. Intensive Care Unit Delirium: a Review of Diagnosis, Prevention, and Treatment. Anesthesiology. 2016;125(6):1229-41.
Brown TM, Boyle MF. Delirium. BMJ. 2002;325(7365):644-7.
Caplan GA, Kurrle SE, Cumming A. Appropriate care for older people with cognitive impairment in hospital. Med J Aust. 2016;205(10):s12-5.
Milbrandt EB, Deppen S, Harrison PL, Shintani AK, Speroff T, Stiles RA, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32(4):955-62.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American psychiatric publishing; 2013.
Wongpakaran N, Wongpakaran T, Bookamana P, Pinyopornpanish M, Maneeton B, Lerttrakarnnon P, et al. Diagnosing delirium in elderly Thai patients: utilization of the CAM algorithm. BMC Fam Pract. 2011;12:65.
Hipp DM, Ely EW. Pharmacological and nonpharmacological management of delirium in critically ill patients. Neurotherapeutics. 2012;9(1):158-75.
Shafiekhani M, Mirjalili M, Vazin A. Psychotropic drug therapy in patients in the intensive care unit - usage, adverse effects, and drug interactions: a review. Ther Clin Risk Manag. 2018;14:1799-812.
Pichot C, Ghignone M, Quintin L. Dexmedetomidine and clonidine: from second- to first-line sedative agents in the critical care setting? J Intensive Care Med. 2012;27(4):219-37.
Giovannitti JA, Jr., Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31-9.
Strange BC. Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr Dis Treat. 2008;4(3):499-506.
Yeo QM, Wiley TL, Smith MN, Hammond DA. Oral agents for the management of agitation and agitated delirium in critically Ill patients. Crit Care Nurs Q. 2017;40(4):344-62.
Seedat YK. Clonidine and guanfacine--comparison of their effects on haemodynamics in hypertension. S Afr Med J. 1985;67(14):557-9.
Jiang S, Czuma R, Cohen-Oram A, Hartney K, Stern TA. Guanfacine for hyperactive delirium: a case series. J Acad Consult Liaison Psychiatry. 2021;62(1):83-8.
Panzer O, Moitra V, Sladen RN. Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists. Crit Care Clin. 2009;25(3):451-69.
McLaughlin M, Marik PE. Dexmedetomidine and delirium in the ICU. Ann Transl Med. 2016;4(11):224.
Farasatinasab M, Kouchek M, Sistanizad M, Goharani R, Miri M, Solouki M, et al. A randomized placebo-controlled trial of clonidine impact on sedation of mechanically ventilated ICU patients. Iran J Pharm Res. 2015;14(1):167-75.
Rubino AS, Onorati F, Caroleo S, Galato E, Nucera S, Amantea B, et al. Impact of clonidine administration on delirium and related respiratory weaning after surgical correction of acute type-A aortic dissection: results of a pilot study. Interact Cardiovasc Thorac Surg. 2010;10(1):58-62.
Gagnon DJ, Riker RR, Glisic EK, Kelner A, Perrey HM, Fraser GL. Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study. Pharmacotherapy. 2015;35(3):251-9.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2019 [cited 2021 May 21]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644-53.
Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically Ill patients: a randomized trial. JAMA. 2009;301(5):489-99.
Shehabi Y, Grant P, Wolfenden H, Hammond N, Bass F, Campbell M, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM Study). Anesthesiology. 2009;111(5):1075-84.
Xuan Y, Fan R, Chen J, Wang Y, Wu J, Yang J, et al., editors. Effects of dexmedetomidine for postoperative delirium after joint replacement in elderly patients : a randomized , double-blind , and placebo-controlled trial. Int J Clin Exp Med. 2018;11(12):13147-57.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพิ์เป็นลิขสิทธิ์ของวารสารโรงพยาบาลชลบุรี